Biofarm (stock symbol BIO), one of the largest pharmaceutical producers in Romania, recorded a 33% increase in turnover compared to Q1 2024. EBITDA grew by 51%, reaching RON 40.5 million, while net profit rose by approximately 57%. These results reflect the efficiency of the company’s operational model and the improved commercial performance. “The results achieved in the first three months of this year confirm the effectiveness of our development strategy, despite a complex economic context